VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                           

 

18th July 2015 - New research

DRY POWDER INHALER FOR PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

A dry powder inhaler has been found to be a viable means of administering L-dopa. Because of its rapid onset of action, pulmonary administration of L-dopa is a possible alternative to the oral administration of L-dopa in Parkinson's Disease patients in an off period. Its means of administration could enable a very quick therapeutic effect. Researchers studied the ability of people with Parkinson's Disease to operate a dry powder inhaler (DPI) correctly during an off period.

They used an instrumented test inhaler with three different resistances to air flow. The volumes inhaled varied from 1.2 litres to 3.5 litres. Total inhalation time and the time to peak inspiratory flow rate both decreased with decreasing inhaler resistance. Nearly all of the patients could hold their breath for at least five seconds after inhalation and most of them could extend this time to ten seconds. The data from this study indicate that patients with Parkinson's disease will be able to use a dry powder inhaler during an off period and they provide an adequate starting point for the development of an L-dopa powder inhaler.

An L-dopa inhaler using L-dopa in liquid form instead of a dry form, that takes only 10 minutes to start having effect, is already undergoing clinical trials in Parkinson's Disease. For more information go to : L-dopa inhaler

Reference : PLoS One [2015] 10 (7) : e0132714 (M.Luinstra, A.W.Rutgers, H.Dijkstra, F. Grasmeijer, P.Hagedoorn, J.M.Vogelzang, H.W.Frijlink, A.H.de Boer) Complete abstract  For more news go to Parkinson's Disease News

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.


PARKINSON'S DISEASE BOOKS from Amazon


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
©2006-2015  Viartis
 
2015-07-19 18:28:17
 
[email protected]